Exploring Cannabis Usage Among Cystic Fibrosis Patients

Doctor checking on Cystic Fibrosis Patient

Recent survey data published in Pediatric Pulmonology reveals that nearly one-third of cystic fibrosis patients have turned to cannabis within the past year, shedding light on its use in symptom management. Conducted by researchers at the University of California, San Francisco, the study surveyed 226 cystic fibrosis patients across the United States, all of whom were aged 13 and above. This article delves into the findings of this significant study, discussing the implications and the growing interest in cannabis and CBD products among this patient population.

Survey Findings

The survey uncovered that 29% of respondents had used cannabis, and 22% had used CBD products in the past year. The primary reasons cited for the consumption of these products were to manage symptoms of anxiety and depression, stimulate appetite, and alleviate arthritic pain. Interestingly, among those who have never used cannabis or CBD products, approximately 50% expressed willingness to do so if marijuana were legal, highlighting the potential for increased usage within legal frameworks.

Usage Motivations

  • Management of anxiety and depression
  • Stimulation of appetite
  • Alleviation of arthritic pain

Legal and Medical Implications

With half of the non-consuming respondents open to using cannabis if it were legal, the study highlights a significant legal and societal impact on the consumption habits of cystic fibrosis patients. The authors of the study call for an expansion in the current knowledge and guidance regarding marijuana and CBD use among this patient group, emphasizing the need for further research to provide accurate counselling for those experiencing benefits.

Call for Further Research

The study concludes with a strong call for further research into the effects and potential benefits of cannabis and CBD use among cystic fibrosis patients. This is echoed by the medical community's growing interest in understanding how these substances can be integrated into symptom management strategies effectively and safely.

External Studies and Research

Related research and surveys have explored the impact of CBD-dominant products on reducing opioid use among pain patients, the role of cannabis compounds in inducing the death of cells associated with liver fibrosis, and the prevalence of CBD use among fibromyalgia patients. These studies provide a broader context for understanding the potential benefits and implications of cannabis and CBD use across different medical conditions.


The use of cannabis and CBD products among cystic fibrosis patients highlights a significant shift towards alternative methods of symptom management. As legal landscapes evolve and further research unfolds, the potential for these substances to play a critical role in improving the quality of life for those living with cystic fibrosis becomes increasingly apparent. However, it is crucial that this exploration is guided by scientific research and medical expertise to ensure the safety and efficacy of cannabis and CBD as part of a comprehensive treatment plan.

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.

Robin Roy Krigslund-Hansen

Robin Roy Krigslund-Hansen

About the author:

Robin Roy Krigslund-Hansen is known for his extensive knowledge and expertise in the fields of CBD and hemp production. With a career spanning over a decade in the cannabis industry, he has dedicated his life to understanding the intricacies of these plants and their potential benefits to human health and the environment. Over the years, Robin has worked tirelessly to promote the full legalization of hemp in Europe. His fascination with the plant's versatility and potential for sustainable production led him to pursue a career in the field.

More about Robin Roy Krigslund-Hansen

Related Products